DK4320112T3 - Pyridinylsubstituerede oxoisoindolinforbindelser - Google Patents
Pyridinylsubstituerede oxoisoindolinforbindelserInfo
- Publication number
- DK4320112T3 DK4320112T3 DK22718513.9T DK22718513T DK4320112T3 DK 4320112 T3 DK4320112 T3 DK 4320112T3 DK 22718513 T DK22718513 T DK 22718513T DK 4320112 T3 DK4320112 T3 DK 4320112T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxoisoindoline
- subtituted
- pyridinyl
- compounds
- subtituted oxoisoindoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4320112T3 true DK4320112T3 (da) | 2025-08-18 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22718513.9T DK4320112T3 (da) | 2021-04-06 | 2022-04-05 | Pyridinylsubstituerede oxoisoindolinforbindelser |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11718601B2 (da) |
| EP (1) | EP4320112B1 (da) |
| JP (1) | JP7821197B2 (da) |
| KR (1) | KR20230165815A (da) |
| AR (1) | AR125298A1 (da) |
| AU (1) | AU2022253242A1 (da) |
| BR (1) | BR112023020077A2 (da) |
| CA (1) | CA3214244A1 (da) |
| CL (1) | CL2023002966A1 (da) |
| CO (1) | CO2023013321A2 (da) |
| DK (1) | DK4320112T3 (da) |
| ES (1) | ES3035755T3 (da) |
| FI (1) | FI4320112T3 (da) |
| HR (1) | HRP20250796T1 (da) |
| HU (1) | HUE072309T2 (da) |
| IL (1) | IL307343A (da) |
| LT (1) | LT4320112T (da) |
| MX (1) | MX2023011715A (da) |
| PE (1) | PE20231941A1 (da) |
| PL (1) | PL4320112T3 (da) |
| PT (1) | PT4320112T (da) |
| RS (1) | RS66982B1 (da) |
| SI (1) | SI4320112T1 (da) |
| SM (1) | SMT202500281T1 (da) |
| TW (1) | TWI867287B (da) |
| WO (1) | WO2022216644A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AR131812A1 (es) * | 2023-02-08 | 2025-05-07 | Bristol Myers Squibb Co | Compuestos y composiciones para la degradación selectiva de proteínas diseñadas |
| KR102834908B1 (ko) * | 2023-09-02 | 2025-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물 |
| US20260078119A1 (en) | 2024-03-22 | 2026-03-19 | Bristol-Myers Squibb Company | Degrader compounds and uses thereof |
| WO2025226767A1 (en) * | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2025234888A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025234887A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2177517E (pt) | 1996-07-24 | 2011-11-10 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| NZ531294A (en) | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2559690T3 (pl) | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| WO2009137095A2 (en) | 2008-05-08 | 2009-11-12 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (da) | 2011-04-15 | 2018-03-17 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| WO2016191178A1 (en) | 2015-05-22 | 2016-12-01 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| KR20240119196A (ko) | 2015-06-04 | 2024-08-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드계 조절인자 및 관련된 이용 방법 |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| JP6921114B2 (ja) | 2016-04-22 | 2021-08-18 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ８（ｃｄｋ８）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ８の分解および使用法 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110062759B (zh) | 2016-09-13 | 2022-05-24 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬 |
| LT3660004T (lt) | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| AU2017382176A1 (en) | 2016-12-21 | 2019-05-30 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| KR20210018199A (ko) * | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| CA3101335C (en) | 2018-06-13 | 2024-01-09 | Biotheryx, Inc. | Fused thiophene compounds |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CU20210002A7 (es) | 2018-07-10 | 2021-08-06 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) |
| CN113423701A (zh) * | 2018-11-13 | 2021-09-21 | 拜欧斯瑞克斯公司 | 取代的异吲哚啉酮 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021015672A2 (pt) * | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| ES3032659T3 (en) * | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230093099A1 (en) | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 PT PT227185139T patent/PT4320112T/pt unknown
- 2022-04-05 SM SM20250281T patent/SMT202500281T1/it unknown
- 2022-04-05 PL PL22718513.9T patent/PL4320112T3/pl unknown
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en not_active Ceased
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko active Pending
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 DK DK22718513.9T patent/DK4320112T3/da active
- 2022-04-05 SI SI202230144T patent/SI4320112T1/sl unknown
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 LT LTEPPCT/US2022/023387T patent/LT4320112T/lt unknown
- 2022-04-05 ES ES22718513T patent/ES3035755T3/es active Active
- 2022-04-05 FI FIEP22718513.9T patent/FI4320112T3/fi active
- 2022-04-05 HR HRP20250796TT patent/HRP20250796T1/hr unknown
- 2022-04-05 RS RS20250660A patent/RS66982B1/sr unknown
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
- 2022-04-05 TW TW111112957A patent/TWI867287B/zh active
- 2022-04-05 JP JP2023561684A patent/JP7821197B2/ja active Active
- 2022-04-05 EP EP22718513.9A patent/EP4320112B1/en active Active
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 MX MX2023011715A patent/MX2023011715A/es unknown
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 HU HUE22718513A patent/HUE072309T2/hu unknown
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en not_active Abandoned
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
-
2024
- 2024-06-25 US US18/740,857 patent/US20240376082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202500281T1 (it) | 2025-09-12 |
| US20240376082A1 (en) | 2024-11-14 |
| RS66982B1 (sr) | 2025-07-31 |
| HUE072309T2 (hu) | 2025-11-28 |
| BR112023020077A2 (pt) | 2023-11-14 |
| PL4320112T3 (pl) | 2025-07-21 |
| EP4320112A1 (en) | 2024-02-14 |
| KR20230165815A (ko) | 2023-12-05 |
| US11718601B2 (en) | 2023-08-08 |
| ES3035755T3 (en) | 2025-09-08 |
| TWI867287B (zh) | 2024-12-21 |
| IL307343A (en) | 2023-11-01 |
| CO2023013321A2 (es) | 2023-10-19 |
| SI4320112T1 (sl) | 2025-09-30 |
| PT4320112T (pt) | 2025-07-07 |
| AR125298A1 (es) | 2023-07-05 |
| TW202304881A (zh) | 2023-02-01 |
| JP7821197B2 (ja) | 2026-02-26 |
| MX2023011715A (es) | 2023-10-12 |
| CA3214244A1 (en) | 2022-10-13 |
| CL2023002966A1 (es) | 2024-02-23 |
| PE20231941A1 (es) | 2023-12-05 |
| HRP20250796T1 (hr) | 2025-08-29 |
| EP4320112B1 (en) | 2025-05-14 |
| LT4320112T (lt) | 2025-07-10 |
| WO2022216644A1 (en) | 2022-10-13 |
| FI4320112T3 (fi) | 2025-07-25 |
| US20230303527A1 (en) | 2023-09-28 |
| US20220324840A1 (en) | 2022-10-13 |
| AU2022253242A1 (en) | 2023-11-23 |
| JP2024515243A (ja) | 2024-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4165024T3 (da) | Cyclobutyldihydroquinolinsulfonamid-forbindelser | |
| EP4129997A4 (en) | Octahydropyrazinodiazanaphthyridine dione compounds | |
| EP4186256C0 (en) | INTER-AGENCY COMMUNICATION VIA AN AD-HOC NETWORK SLICE | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| EP4293025C0 (en) | COMPOSED WITH 4-AMINOQUINAZOLINE | |
| EP4149556C0 (en) | PEG LIPIDOIDS COMPOUNDS | |
| EP4137404A4 (en) | Multicopter | |
| EP4199925B1 (en) | ORETIN RECEPTOR AGONISTS CYCLOPENTAPYRROLE | |
| EP4107782A4 (en) | MICROARRAYS | |
| EP4222352A4 (en) | BOLTER | |
| EP4272364A4 (en) | TA NTN REPORT | |
| EP4223314A4 (en) | LIPID NANOPARTICLE | |
| EP4208295C0 (de) | Fleischwolf | |
| EP4143199C0 (en) | NUCLEOTIDE PROMEDICINAL COMPOUNDS | |
| EP3957265A4 (en) | MICROSCOPE COVER | |
| EP4063561C0 (en) | REFINER SEGMENT | |
| EP4204218C0 (en) | TAPE LAYING HEAD | |
| EP4163277C0 (en) | NEW PYRAZOLE DERIVATIVES | |
| EP4274436A4 (en) | Combination therapies | |
| EP4192823C0 (en) | TRIAZOLES DIFLUOROMETHYL-PYRIDIN-2-YL | |
| EP4154884A4 (en) | Anti-sars-cov-2 durg | |
| EP4137402A4 (en) | MULTICOPTER | |
| IL313590A (en) | Compounds | |
| PT4038149T (pt) | Compostos anti-incrustação | |
| EP4228051A4 (en) | LEAD STORAGE BATTERY |